Arixtra safety update
This article was originally published in Pharmaceutical Approvals Monthly
FDA approves labeling revision for Organon/Sanofi-Synthelabo's deep vein thrombosis agent Arixtra (fondaparinux) Dec. 4, removing a caveat that improved efficacy seen versus Aventis' Lovenox (enoxaparin) may have been influenced by timing of the first dose and eliminating a statement that there was a higher bleeding rate with Arixtra. In the initial review, FDA felt that the rate of bleeding and venous thromboembolisms in clinicals might have been affected by deviance from the dosing schedule (Pharmaceutical Approvals Monthly, May 1, 2002, p. 33). Other labeling revisions include the addition of VTE relative risk reduction figures. Revised labeling could allow the companies to boost sales; Arixtra's launch has been slower than expecte
You may also be interested in...
Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.